Genentech's
lung cancer drug Alecensa received FDA's conditional approval for the treatment of ALK - positive lung cancer.
Eli Lilly takes a win over generic challenger Actavis as London court rules in its favor in a patent case involving
lung cancer drug Alimta.
After identifying three different types of resistance to a promising investigational
lung cancer drug in a phase 1 trial, a team of researchers led by Dana - Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors» constant and varied molecular shape - shifting.
The lung cancer drug — called gefitinib — helps by blocking a protein that is known to encourage cell growth, and which was found to be present in high levels at the site of ectopic pregnancies.
Women with ectopic pregnancies could be spared surgery if they are treated with
a lung cancer drug, a study suggests.
The team studied
a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.
Tamara Minko and colleagues at Rutgers University in New Jersey decided to encapsulate
the lung cancer drug doxorubicin in fatty bubbles that are small and light enough to be inhaled.
Rep. Brian Higgins on Friday called on the Trump administration to avoid policy changes that would endanger Roswell Park Cancer Institute's work on a promising
lung cancer drug developed in Cuba.
Rep. Brian Higgins called on the Trump administration to avoid policy changes that would endanger Roswell Park Cancer Institute's work on a promising
lung cancer drug developed in Cuba.
HERERA: Merck (NYSE: MRK) was one of the best performing stocks on the blue chip Dow index today, after the drug company «s new type of
lung cancer drug performed better than expected in a highly anticipated clinical trial.
The timing of the news report alarmed investors, coming as the company waits for all - important data from
a lung cancer drug trial which is seen as a game - changer for Astra.
said they will discontinue a late - stage trial of their experimental
lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.
PACKAGING
lung cancer drugs in inhalable bubbles could allow bigger doses to be delivered to tumours without the side effects associated with chemotherapy.
Cancer Institute of NJ Investigates Promising Immunotherapy for Toughest
Lung Cancers Drug Discovery & Development — May 14, 2015
Waco How Chip Joanna Gaines are renovating Wacos reputation, one home time medical speed - dating study will
lung cancer drugs patients.
Not exact matches
Darzalex, however, has not yet reached its peak potential as the
drug moves into earlier stages of the disease and is being tested on solid tumours like
lung cancer.
The Hong Kong - listed company has two blockbuster
drugs on its roster — anlotinib for
lung cancer and tenofovir for hepatitis B — and a few blockbuster generics aiming for approval before 2021.
Analysts at the investment bank said the Dow member's sales could boom because of Keytruda, a blockbuster
drug used to treat
lung cancer.
This
drug has already staked its claim in the world of next - gen «checkpoint inhibitor»
cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell
lung cancer (NSCLC).
Since then, the companies have been scrambling to rack up indications for the rival
drugs, which are both approved for treating melanoma and
lung cancer.
The
drug had $ 942 million in global 2015 sales (versus $ 566 million for Keytruda) and, according to the company, has been prescribed to 60 % of new
lung cancer patients.
The company actually beat Wall Street profit estimates largely thanks to its superstar
cancer immunotherapy
drug Keytruda, which has been shown to best chemotherapy in helping
lung cancer patients live longer and given Merck a leg up over rivals like Bristol - Myers Squibb's immune therapy Opdivo.
That medicine made by
drug giant Merck (NYSE: MRK) showed some new results today in
lung cancer that are being called unprecedented.
They'll also jointly market Pfizer's
drug Xalkori, which is approved in more than 75 countries for treating non-small cell
lung cancer in patients with a certain genetic mutation.
Merck already has an FDA approved immunotherapy
drug with KEYTRUDA, a treatment for non-small cell
lung cancer.
Celgene will help fund a study with BeiGene's
lung cancer hopeful, tislelizumab, and in return pay BeiGene royalties on any U.S. sales of the
drug.
Delivering
cancer drugs directly to the
lungs is the obvious answer, but how?
A late breaking subanalysis of the phase III CONVERT trial presented at the European
Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SC
Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (
Cancer Conference (ELCC) shows that white blood cell boosting
drugs are safe during concurrent chemo - radiotherapy of small cell
lung cancer (SC
lung cancer (
cancer (SCLC).
Other trials of this
drug target in
lung cancer have not worked, and the
drugs» effects in colorectal
cancer are also questionable, Stambolic says.
In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy
drug nivolumab, researchers found that people with squamous - non-small cell
lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.
«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and
Drug Administration approval in March to treat such patients whose
lung cancer progressed, despite standard chemotherapy.
The abstract title was: Attempt to Validate
Drug Repositioning for Metastatic Small Cell
Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?
«Immunotherapy
drug improves survival for common form of
lung cancer.»
Pembrolizumab, or pembro, an immunotherapy
drug that unmasks
cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Ar
cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating
lung cancers, according to a study by
Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Ar
Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.
Colon
cancer requires different
drug regimens than
lung, breast, or skin
cancer.
«Clinical trial using immunotherapy
drug combinations to treat
lung cancer appears safe.»
«Blood pressure
drug may boost effectiveness of
lung cancer treatment.»
The
drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell
lung cancer, which accounts for 85 per cent of all
lung cancer cases.
«We urgently need new treatments for
lung cancer patients, and this research suggests we can boost the effectiveness of an existing
drug, rather than switch to another new expensive treatment.
Whereas most conventional scientists focus on a single system or disease, Butte earned tenure recently with a dossier of advances in diabetes, obesity, and transplant rejection, and the discovery of new
drugs for
lung cancer and other diseases.
«Our findings suggest that this new
drug combination would also help patients with this type of aggressive breast
cancer as well as other
cancers, such as
lung, prostate and ovarian
cancers,» Dr. Rassool says.
A one - two combo punch using two currently available
drugs could be an effective treatment for the majority of
lung cancers, a study by scientists with UT Southwestern's Simmons
Cancer Center shows.
Both
drugs are approved for treating metastatic melanoma, and Opdivo is also approved for squamous
lung cancer.
Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell
lung cancers that have a variant of EGFR, but the two -
drug combo could potentially work for all non-small cell
lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.
A blood pressure
drug may make a type of
lung cancer treatment more effective, suggests a new study.
The scientists identified several, including the investigational
cancer drug BEZ235, which blocked a key metabolic pathway in flu - infected human
lung epithelial cells.
Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the
drug giant Novartis, the trial also found fewer cases of
lung cancer in those on the treatment, rekindling basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.
«Our study results suggest a new
drug cocktail that is effective in both human
lung cancer cell lines and fly models,» says Cagan.
A
drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Si
drug approved by the Food and
Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Si
Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering
drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Si
drug may show promise in controlling
cancer growth in patients with non-small cell
lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.
Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational
drug brigatinib against ALK + non-small cell
lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.